The variation in stroke outcomes among individuals is substantial, and studying proteins can help uncover the biological mechanismsbehind this variability. By employing various proteomic techniques, researchers have identified numerous proteins and proteomes that could serve as biomarkers for stroke. Conducting an exploratory analysis to discover proteins linked to stroke severity or outcomes may expedite the investigation of potential candidate molecules. However, given the vast array of possible targets and the intricate nature of biological systems, pinpointing significant protein biomarkers for focused analysis can be quite challenging.
Ace Therapeutics' bioanalytical team has extensive experience in biomarker development, characterization and validation. We provide comprehensive protein biomarker development services to help clients study the pathophysiology, diagnosis, and prognosis of stroke. We are able to help discover stroke-related protein biomarkers, measure and interpret their changes in assay systems, and link them to drug development programs. Our protein biomarker development services deliver accurate and reliable results.
Our scientists use advanced proteomics techniques (e.g., mass spectrometry, array-based methods) to develop and validate a broad range of protein biomarkers for pharmaceutical and biotech companies focused on stroke.
Type of Proteins | Examples |
Proteins involved in ischemic brain injury | S100 calcium binding protein B (S-100B), neuron-specific enolase (NSE), myelin basic protein (MBP), glial fibrillary acidic protein (GFAP) |
Proteins involved in inflammation and immune response | C-reactive protein (CRP), interleukin 6 (IL-6), tissue necrosis factor-alpha (TNF-alpha), vascular cell adhesion protein 1 (VCAM 1), intercellular adhesion molecule 1 (ICAM 1), N-methyl-d-aspartic acid (NMDA) receptor, matrix metalloproteinase (MMP) |
Proteins involved in acute thrombosis | Fibrinogen, D-dimer, vascular hemophilic factor (vWF) |
Other proteins associated with stroke | PARK7, nucleotide diphosphate kinase A (NDKA), B-type neurotrophic growth factor (BDNF) |
Ace Therapeutics has a wide range of capabilities to support the identification and analysis of protein biomarkers for stroke. We have extensive experience in biomarker evaluation, including assay development and validation. Leverage our expertise and state-of-the-art technology to advance your stroke drug development. Please contact us for high-quality biomarker development services.
We are committed to accelerating progress in stroke research and drug development.